Lapsi Health’s Keikku 2.0 combines auscultation, AI diagnostics, and ambient documentation in the first FDA-cleared multimodal digital stethoscope.
A European-American health technology startup is bringing what it claims is a first-of-its-kind innovation to the digital stethoscope market: a device that simultaneously listens to heart and lung sounds, generates clinical documentation, and provides AI-powered diagnostic support—all in a single tool.
Lapsi Health, with offices in Amsterdam and Houston, announced the launch of Keikku 2.0, which the company describes as the first FDA-cleared digital stethoscope integrating auscultation, ambient documentation, and AI-powered disease detection. The device aims to streamline clinical workflows by addressing two persistent pain points: time-consuming EHR documentation and the challenge of detecting subtle cardiac and pulmonary abnormalities during routine exams.
According to the American Medical Association, primary care physicians spend an average of 36 minutes per patient visit on charting in electronic health record systems, according to the company, with some of this work occurring outside clinic hours. Keikku 2.0 attempts to compress these tasks by automatically generating ready-to-use clinical notes that integrate directly into major EHR platforms while simultaneously analyzing auscultation data for signs of cardiac murmurs and lung disease.
Multimodal Design: Combining Documentation and Diagnostics
The device’s core differentiator, according to Lapsi Health, lies in its multimodal integration. Unlike standalone digital stethoscopes focused solely on sound amplification and AI diagnostics, or ambient scribe tools that only handle documentation, Keikku 2.0 combines both functions in a single workflow. Clinicians can listen, document, and receive diagnostic insights without switching tools or devices.
“Keikku 2.0 is the first multimodal device to combine clinical, administrative, and AI power in one tool,” said Jhonatan Bringas Dimitriades, MD, CEO and co-founder of Lapsi Health. “For the first time, physicians can listen, document, and diagnose in real time with a single device. That means less time on paperwork and more focus on patients. We’re proud to bring this innovation to market and give clinicians back hours each day to deliver better patient care.”
The device’s high-definition ambient microphones capture clinical-grade sound even in noisy environments, according to the company, while maintaining patient privacy through built-in cybersecurity and encrypted data transmission. Keikku 2.0 works with all major scribe technologies, including Lapsi Health’s proprietary Keikku AI platform as well as leading third-party ambient documentation solutions, providing flexibility for clinics and hospitals with existing vendor relationships.
The device’s AI-powered auscultation analytics detect cardiac murmurs and abnormal lung sounds that may indicate disease, providing real-time, data-driven insights during routine physical exams. By converting sound into structured data, the platform aims to support more personalized and precise clinical decision-making.
“As physicians, we designed Keikku 2.0 to fit seamlessly into clinical workflows. Every feature was built to improve efficiency and reduce stress for healthcare providers,” said Diana van Stijn, MD, PhD, Chief Medical Officer and co-founder at Lapsi Health. “We set out to create a tool that feels familiar — like a smart medical assistant — to reduce burden and free clinicians to focus their energy on patient care.”
Competitive Landscape: A Crowded but Evolving Market
Lapsi Health enters a digital stethoscope market already populated by established players, each with distinct technological approaches and clinical validation. Eko Health, the most prominent competitor, has secured multiple FDA clearances for AI algorithms that detect atrial fibrillation, structural heart murmurs, and low ejection fraction—a key indicator of heart failure. Used by more than 600,000 providers globally, Eko’s platform has been validated through collaborations with Mayo Clinic and has received breakthrough designation from the FDA.
Eko’s devices, including the CORE 500, combine digital stethoscope functionality with ECG capabilities and AI-powered disease detection. The company has focused intensively on cardiac diagnostics, with algorithms trained on datasets exceeding 100,000 ECG-echocardiogram pairs. This depth of clinical validation and market penetration positions Eko as the incumbent leader in AI-enhanced auscultation.
3M Littmann, a legacy brand with decades of dominance in traditional stethoscopes, has also entered the digital market with its CORE Digital Stethoscope. The device provides up to 40x sound amplification, active noise cancellation, and Bluetooth connectivity for sound recording and sharing through integration with Eko’s software platform. Littmann’s approach leverages its established brand recognition and distribution channels, offering a digital upgrade path for clinicians already loyal to the Littmann name.
Thinklabs One, another competitor, emphasizes portability and sound amplification, delivering up to 100x amplification in a compact, tubeless design that connects directly to headphones. The device targets telemedicine applications and clinicians seeking maximum portability, though it lacks the integrated AI diagnostic capabilities that Keikku 2.0 and Eko offer.
What distinguishes Keikku 2.0 in this landscape is its integration of ambient clinical documentation—functionality that none of its direct digital stethoscope competitors currently provide. While Eko, Littmann, and Thinklabs focus on enhanced auscultation and diagnostic AI, Keikku 2.0 attempts to solve administrative burden challenges alongside clinical ones, positioning itself as both a diagnostic tool and a workflow efficiency solution.
This dual value proposition could appeal to healthcare organizations seeking to consolidate vendor relationships and reduce the number of separate tools clinicians must manage. However, it also introduces complexity: the device must excel at both auscultation/diagnostics and documentation to justify its multimodal design. Weakness in either domain could undermine its competitive positioning.
Strategic Implications and Market Positioning
For health systems evaluating digital stethoscope options, Keikku 2.0’s multimodal approach presents both opportunity and risk. The potential to address documentation burden while improving diagnostic accuracy could drive adoption, particularly among primary care practices where both challenges are acute. According to the company, reducing charting time by automating note generation could enable physicians to see more patients or spend additional time on complex cases.
The device’s compatibility with third-party scribe platforms also provides flexibility, allowing organizations already invested in specific ambient documentation vendors to maintain those relationships while adding Keikku’s auscultation capabilities. This vendor-agnostic approach could accelerate adoption by reducing switching costs.
However, Keikku 2.0 faces significant challenges entering a market where competitors have established clinical validation, regulatory clearances across multiple indications, and substantial installed bases. Eko’s algorithms, for example, have been independently validated by Imperial College London and deployed across NHS clinics in the UK. Littmann carries brand equity built over decades. Keikku Health must demonstrate that its multimodal approach delivers measurably better outcomes or efficiency gains to justify displacing these incumbents.
The device is currently wireless and Bluetooth-enabled, requiring pairing with a smartphone—a potential limitation compared to standalone devices. According to the company, future technology development aims to enable independent operation, which could enhance portability and reduce dependency on additional hardware.
Adoption Barriers and Implementation Challenges
Several factors will influence whether Keikku 2.0 gains traction beyond early adopters. Clinical validation remains critical. While the device has received FDA Class II clearance, published peer-reviewed studies demonstrating diagnostic accuracy, documentation quality, and workflow impact will be essential for broader adoption. Clinicians and health system decision-makers increasingly demand evidence that new tools improve outcomes, not just features.
Integration complexity also presents challenges. The device must connect reliably with multiple EHR systems and scribe platforms, handle varied clinical workflows across specialties, and function consistently in diverse care settings—from hospital rounds to outpatient clinics to field medicine. Poor integration experiences could limit adoption regardless of the device’s inherent capabilities.
Pricing and reimbursement considerations matter significantly. Digital stethoscopes range from several hundred to over a thousand dollars, with additional subscription costs for AI features and software platforms. Healthcare organizations operating under tight capital budgets will scrutinize whether the efficiency gains and diagnostic improvements justify the investment compared to less expensive alternatives.
Clinician behavior change represents another hurdle. Physicians accustomed to traditional stethoscopes may resist adopting new devices, particularly if they perceive them as complicated or unreliable. Training requirements, device familiarity, and trust in AI-generated insights all influence whether clinicians actually use new tools in practice rather than reverting to familiar equipment.
Privacy and data security concerns also apply. The device captures both audio recordings of patient encounters and physiological data, requiring robust HIPAA-compliant security measures. Any breach or perceived vulnerability could undermine adoption, particularly given heightened awareness of healthcare data risks.
Looking Ahead: Convergence of Diagnostic and Administrative AI
Lapsi Health’s approach reflects broader convergence trends in healthcare AI: tools that address multiple pain points simultaneously rather than optimizing single functions. As administrative burden and diagnostic accuracy both rank among physicians’ top concerns, technologies that tackle both challenges could gain advantage over point solutions.
For clinicians navigating documentation overload and time pressure, devices that automate charting while enhancing diagnostic confidence could genuinely improve daily work experience. The ability to conduct physical exams without worrying about capturing detailed notes afterward, while simultaneously receiving AI-supported insights about potential cardiac or pulmonary abnormalities, represents meaningful workflow improvement—if the technology performs reliably.
For patients, the implications center on physician attention and diagnostic accuracy. If Keikku 2.0 and similar tools reduce the time physicians spend on documentation, that time can redirect toward patient communication, care coordination, and clinical reasoning. Enhanced detection of subtle heart murmurs or lung abnormalities during routine exams could enable earlier intervention and better outcomes, particularly for conditions that often go undiagnosed until they become acute.
Ultimately, the success of multimodal devices like Keikku 2.0 will depend less on feature lists than on execution: whether they reliably improve clinical workflows without adding complexity, whether their AI delivers actionable insights physicians trust, and whether they meaningfully enhance the care experience for both providers and patients. In a market where established competitors already offer robust solutions, Lapsi Health’s innovation lies not in inventing digital stethoscopes or AI diagnostics, but in combining them with documentation automation in ways that genuinely serve the clinicians and patients at the center of care.
– This original article was created with AI support.
